2Zhang JT.The multi-structural feature of the multidrug resistance gene product P-glycoprotein; implications for its mechanism of action (hypothesis)[J].Mol Membr Biol,2001,18 (2):145-152.
4Steiner E,Holzmann K,Elbling L,et al.Cellular functions of vaults and their involvement in multidrug resistance[J].Curr Drug Targets,2006,7 (8):923-934,
5Steiner E,Holzmann K,Elbling L,et al.The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals[J].J Cell Sci,2006,119 (3):459-469.
6Snyder RD.Assessment of atypical DNA intercalating agents in biological and in silico systems[J].Murat Res,2007,623 (1-2):72-82.
7Stathopoulos GP,Kapranos N,Manolopoulos L,et al.Topoisomerase Ⅱ alpha expression in squamous cell carcinomas of the head and neck[J].Anticancer Res,2000,20:177-182.
7Sambrook J Fritsch EF Maniatis T 等主编 金冬雁 黎盂枫 等译.分子克隆 第2版[M].北京:科学出版社,1996.889—890.
8[1]Jimenez R E,Zalupski M M,Frank J J,et al. Multidrug resistance phenotype in high grade soft tissue sarcoma.Cancer, 1999,86: 976- 981.
9[2]Giles F J. Kantarjian H M, Cortes J, et al. Multidrug resistance protein expression in chronic myeloid leukemia. Cancer, 1999,86: 805 - 813.
10[3]Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: Correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst, 1994,86:1539- 1545.
